

**Information for Healthcare Professionals:  
Updated Prescribing Information for Zanaflex® [tizanidine HCL]**

According to Medwatch, Acorda Therapeutics and FDA informed healthcare professionals of changes to the CONTRAINDICATIONS and WARNINGS Sections of the product labeling for Zanaflex, a drug used to treat spasticity. In pharmacokinetic studies where tizanidine was coadministered with either fluvoxamine or ciprofloxacin (CYP1A2 inhibitors), the serum concentration of tizanidine was significantly increased and potentiated its hypotensive and sedative effects. Although there are no clinical studies evaluating the effects of other CYP1A2 inhibitors on tizanidine, coadministration of tizanidine with other CYP1A2 inhibitors (zileuton, other fluoroquinolones, antiarrhythmics, cimetidine, famotidine, oral contraceptives, acyclovir and ticlopidine) should be avoided.

The complete MedWatch 2007 safety summary, including a link to the manufacturer's Dear Healthcare Provider Letter regarding this issue, is available at:

<http://www.fda.gov/medwatch/safety/2007/safety07.htm#Zanaflex>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at [http://www.spine.org/spine\\_safety\\_notices.cfm](http://www.spine.org/spine_safety_notices.cfm). This information is provided as a service for information and education only.